Recent developments of peptidomimetic HIV-1 protease inhibitors

Current Medicinal Chemistry

Volumn 18, Issue 29, 2011, Pages 4513-4537

  Qiu, X ^a   Liu, Z P ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Antiviral; Drug resistance; HIV; Human immunodeficiency virus; Ligands; Multidrug resistant; Mutant HIV 1 variants; Peptidomimetic; Protease inhibitors; Substrate based drug design; Substrate envelope hypothesis

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; FOSAMPRENAVIR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; NELFINAVIR; PEPTIDOMIMETIC AGENT; POL PROTEIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CROSS RESISTANCE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PROTEIN FUNCTION; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VIRUS PARTICLE;

ANIMALS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; PEPTIDOMIMETICS;

EID: 80052987412     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797287566     Document Type: Review

References (62)

1. Brookmeyer, R. Measuring the HIV/AIDS epidemic: approaches andchallenges. Epidemiol. Rev., 2010, 32, 26-37.
2. Mitsuya, H.; Maeda, K.; Das, D.; Ghosh, A.K. Development of proteaseinhibitors and the fight with drug-resistant HIV-1 variants. Adv. Pharmacol.,2008, 56, 169-197.
3. Spivak, A.M.; Siliciano, R.F. Using highly active antiretroviral therapy todecrease perioperative HIV-1 transmission risk. AIDS, 2010, 24, 1603-1404.
4. Tsantrizos, Y.S. Peptidomimetic therapeutic agents targeting the proteaseenzyme of the human immunodeficiency virus and hepatitis C virus. Acc.Chem. Res., 2008, 41, 1252-1263.
5. Brik, A.; Wong, C.-H. HIV-1 protease: mechanism and drug discovery. Org.Biomol. Chem., 2003, 1, 5-14.
6. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years afterthe discovery of HIV. Int. J. Antimicrob. Agents, 2009, 33, 307-320.
7. Armbruster, C. HIV-1 infection: recent developments in treatment andcurrent management strategies. Anti-Infect. Agents Med. Chem., 2008, 7,201-214.
8. Anderson, J.; Schiffer, C.; Lee, S.-K.; Swanstrom, R.V. Viral proteaseinhibitors. Handb. Exp. Pharmacol., 2009, 189, 85-110.
9. Wensing, A.M.J.; van Maarseveen, N.M.; Nijhuis, M. Fifteen years of HIVprotease inhibitors: raising the barrier to resistance. Antiviral Res., 2010, 85,59-74.
10. Mastrolorenzo, A.; Rusconi, S.; Scozzafava, A.; Barbaro, G.; Supuran, C.T.Inhibitors of HIV-1 protease: current state of the art 10 years after theirintroduction. From antiretroviral drugs to antifungal, antibacterial andantitumor agents based on aspartic protease inhibitors. Curr. Med. Chem.,2007, 14, 2734-2748. (Pubitemid 350130917)
11. Ali, A.; Bandaranayake, R.M.; Cai, Y.; King, N.M.; Kolli, M.; Mittal, S.;Murzycki, J.F.; Nalam, M.N.L.; Nalivaika, E.A.; Özen, A.; Prabu-Jeyabalan,M.M.; Thayer, K.; Schiffer, C.A. Molecular basis for drug resistance in HIV-1 protease. Viruses, 2010, 2, 2509-2535.
12. Hue, S.; Gifford, R.J.; Dunn, D.; Fernhill, E.; Pillay, D. Demonstration ofsustained drug-resistant human immunodeficiency virus type 1 lineagescirculating among treatment-naïve individuals. J. Virol., 2009, 83, 2645-2654.
13. Kovalevsky, A.Y.; Liu, F.; Leshchenko, S.; Ghosh, A.K.; Louis, J.M.;Harrison, R.W.; Weber, I.T. Ultra-high resolution crystal structure of HIV-1protease mutant reveals two binding sites for clinical inhibitor TMC114. J.Mol. Biol., 2006, 363, 161-173. (Pubitemid 44437563)
14. Ghosh, A.K.; Chapsal, B.D.; IWeber, I.T; Mitsuya, H. Design of HIVprotease inhibitors targeting protein backbone: an effective strategy forcombating drug resistance. Acc. Chem. Res., 2008, 41, 78-86.
15. Chellappan, S.; Kairys, V.; Fernandes, M.X.; Schiffer, C.; Gilson, M.K.Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1protease. Proteins: Strut. Funct. Bioinf., 2007, 68, 561-567. (Pubitemid 46981948)
16. Chellappan, S.; Reddy, G.S.K.K.; Ali, A.; Nalam, M.N.L.; Anjum, S.G.;Cao, H.; Kairys, V.; Fernandes, M.X.; Altman, M.D.; Tidor, B.; Rana, T.M.;Schiffer, C.A.; Gilson, M.K. Design of mutation-resistant HIV proteaseinhibitors with the substrate envelope hypothesis. Chem. Biol. Drug Des.,2007, 69, 298-313. (Pubitemid 46817456)
17. Nalam, M.N.; Schiffer, C.A. New approaches to HIV protease inhibitor drugdesign II: testing the substrate envelope hypothesis to avoid drug resistanceand discover robust inhibitors. Curr. Opin. HIV AIDS, 2008, 3, 642-646.
18. Ekegren, J.K.; Ginman, N.; Johansson, A.; Wallberg, H.; Larhed, M.;Samuelsson, B.; Unge, T.; Hallberg, A. Microwave-accelerated synthesis ofP1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol inthe transition-state mimicking scaffold. J. Med .Chem., 2006, 49, 1828-1832. (Pubitemid 43376526)
19. Wu, X.Y.; Oehrngren, P.; Ekegren, J.K.; Unge, J.; Unge, T.; Wallberg, H.;Samuelsson, B.; Hallberg, A.; Larhed, M. Two-carbon-elongated HIV-1protease inhibitors with a tertiary-alcohol-containing transition-state mimic.J. Med. Chem., 2008, 51, 1053-1057. (Pubitemid 351304714)
20. Mahalingam, A.K.; Axelsson, L.; Ekegren, J.K.; Wannberg, J.; Kihlstrom, J.;Unge, T.; Wallberg, H.; Samuelsson, B.; Larhed, M.; Hallberg, A. HIV-1protease inhibitors with a transition-state mimic comprising a tertiaryalcohol: improved antiviral activity in cells. J. Med. Chem., 2010, 53, 607-615.
21. (a)Mimoto, T.; Kato, R.; Takaku, H.; Nojima, S.; Terashima, K.; Misawa,S.; Fukazawa, T.; Ueno, T.; Sato, H.; Shintani, M.; Kiso, Y.; Hayashi, H.Structure-activity relationship of small-sized HIV protease inhibitorscontaining allophenylnorstatine. J. Med. Chem., 1999, 42, 1789-1802 (Pubitemid 29244972)
22. (b)Yoshimura, K.; Kato, R.; Yusa, K.; Kavlick, M.F.; Maroun, V.; Nguyen, A.;Mimoto, T.; Ueno, T.; Shintani, M.; Falloon, J.; Masur, H.; Hayashi, H.;Erickson, J.; Mitsuya, H. JE-2147: A dipeptide protease inhibitor (PI) thatpotently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. U.S.A.,1999, 96, 8675-8680. (Pubitemid 29354850)
23. Mimoto, T.; Nojima, S.; Terashima, K.; Takaku, H.; Shintani, M.; Hayashi,H. Structure-activity relationships of novel HIV-1 protease inhibitorscontaining the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.Bioorg. & Med. Chem., 2008, 16, 1299-1308. (Pubitemid 351191770)
24. Bonini, C.; Chiummiento, L.; De Bonis, M.; Di Blasio, N.; Funicello, M.;Lupattelli, P.; Pandolfo, R.; Tramutola, F.; Berti, F. Synthesis of new thienylring containing HIV-1 protease inhibitors: promising preliminarypharmacological evaluation against recombinant HIV-1 proteases. J. Med.Chem., 2010, 53, 1451-1457.
25. (a)Ghosh, A.K.; Kulkarni, S.; Anderson, D.D.; Hong, L.; Baldridge, A.;Wang, Y.F.; Chumanevich, A.A.; Kovalevsky, A.Y.; Tojo, Y.; Amano, M.;Koh, Y.; Tang, J.; Weber, I.T.; Mitsuya, H. Design, synthesis, protein-ligandX-ray structure, and biological evaluation of a series of novel macrocyclichuman immunodeficiency virus-1 protease inhibitors to combat drugresistance. J. Med. Chem.., 2009, 52, 7689-7705
26. (b)Tojo, Y.; Koh, Y.;Amano, M.; Aoki, M.; Das, D.; Kulkarni, S.; Anderson, D.D.; Ghosh, A.K.;Mitsuya, H. Novel protease inhibitors (PIs) containing macrocycliccomponents and 3(R),3a(S),6a(R)-bis- tetrahydrofuranylurethane that arepotent against multi-PI-resistant HIV-1 variants in vitro. Antimicrob. AgentsChemother., 2010, 54, 3460-3470.
27. Miller, J.F.; Andrews, C.W.; Brieger, M.; Furfine, E.S.; Hale, M.R.; Hanlon,M.H.; Hazen, R.J.; Kaldor, I.; McLean, E.W.; Reynolds, D. Ultra-potent P1modified arylsulfonamide HIV protease inhibitors: the discovery ofGW0385. Bioorg. Med. Chem. Lett., 2006, 16, 1788-1794. (Pubitemid 43267351)
28. Meredith, J.A.; Wallberg, H.; Vrang, L.; Oscarson, S.; Parkes, K.; Hallberg,A.; Samuelsson, B., Design and synthesis of novel P2 substituents in diolbasedHIV protease inhibitors. Eur. J. Med. Chem., 2010, 45, 160-170.
29. Ali, A.; Reddy, G.S.K.K.; Cao, H.; Anjum, S.G.; Nalam, M.N.L.; Schiffer,C.A.; Rana, T.M. Discovery of HIV-1 protease inhibitors with picomolaraffinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2ligands. J. Med .Chem., 2006, 49, 7342-7356. (Pubitemid 44913395)
30. Ali, A.; Reddy, G.S.K.K.; Nalam, M.N.; Anjum, S.G.; Cao, H.; Schiffer,C.A.; Rana, T.M. Structure-based design, synthesis, and structure-activityrelationship studies of HIV-1 protease inhibitors incorporatingphenyloxazolidinones. J. Med. Chem., 2010, 53, 7699-7708.
31. Reddy, G.S.K.K.; Ali, A.; Nalam, M.N.L.; Anjum, S.G.; Cao, H.; Nathans,R.S.; Schiffer, C.A.; Rana, T.M. Design and synthesis of HIV-1 proteaseinhibitors incorporating oxazolidinones as P2/P2' ligands inpseudosymmetric dipeptide isosteres. J. Med .Chem., 2007, 50, 4316-4328. (Pubitemid 47378831)
32. Ghosh, A.K.; Sridhar, P.R.; Leshchenko, S.; Hussain, A.K.; Li, J.F.;Kovalevsky, A.Y.; Walters, D.E.; Wedekind, J.E.; Grum-Tokars, V.; Das,D.; Koh, Y.; Maeda, K.; Gatanaga, H.; Weber, I.T.; Mitsuya, H. Structurebaseddesign of novel HIV-1 protease inhibitors to combat drug resistance. J.Med. Chem., 2006, 49, 5252-5261. (Pubitemid 44260221)
33. Ghosh, A.K.; Leshchenko-Yashchuk, S.; Anderson, D.D.; Baldridge, A.;Noetzel, M.; Miller, H.B.; Tie, Y.F.; Wang, Y.F.; Koh, Y.; Weber, I.T.;Mitsuya, H. Design of HIV-1 protease inhibitors with pyrrolidinones andoxazolidinones as novel P1'-Ligands to enhance backbone-bindinginteractions with protease: synthesis, biological evaluation, and proteinligandX-ray studies. J. Med .Chem., 2009, 52, 3902-3914.
34. Amano, M.; Koh, Y.; Das, D.; Li, J.F.; Leschenko, S.; Wang, Y.F.; Boross,P.I.; Weber, I.T.; Ghosh, A.K.; Mitsuya, H. A novel bistetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI),GRL-98065, is potent against multiple-PI-resistant human immunodeficiencyvirus in vitro. Antimicrob. Agents Chemother., 2007, 51, 2143-2155. (Pubitemid 46903107)
35. Ghosh, A.K.; Gennna, S.; Takayama, J.; Baldridge, A.; Leshchenko-Yashchuk, S.; Miller, H.B.; Wang, Y.F.; Kovalevsky, A.Y.; Koh, Y.; Weber,I.T.; Mitsuya, H. Potent HIV-1 protease inhibitors incorporating mesobicyclicurethanes as P2-ligands: structure-based design, synthesis, biologicalevaluation and protein-ligand X-ray studies. Org. Biomol. Chem., 2008, 6,3703-3713.
36. Ghosh, A.K.; Xu, C.X.; Rao, K.V.; Baldridge, A.; Agniswamy, J.; Wang,Y.F.; Weber, I.T.; Aoki, M.; Miguel, S.G.P.; Amano, M.; Mitsuya, H.Probing multidrug-resistance and protein-ligand interactions withoxatricyclic designed ligands in HIV-1 protease inhibitors. ChemMedChem,2010, 5, 1850-1854.
37. Ghosh, A.K.; Chapsal, B.D.; Baldridge, A.; Steffey, M.P.; Walters, D.E.;Koh, Y.; Amano, M.; Mitsuya, H. Design and synthesis of potent HIV-1protease inhibitors incorporating hexahydrofuropyranol-derived high affinityP2 ligands: structure-activity studies and biological evaluation. J. Med.Chem., 2011, 54, 622-634.
38. Ghosh, A.K.; Martyr, C.D.; Steffey, M.; Wang, Y.-F.; Agniswamy, J.;Amano, M.; Weber, I.T.; Mitsuya, H. Design, synthesis, and X-ray structureof substituted bis-tetrahydrofuran (bis-THF)-derived potent HIV-1 Proteaseinhibitors. ACS Med. Chem. Lett., 2011, 2, 298-302.
39. Hohlfeld, K.; Tomassi, C.; Wegner, J.K.; Kesteleyn, B.; Linclau, B.Disubstituted bis-THF moieties as new P2 ligands in nonpeptidal HIV-1protease inhibitors. ACS Med. Chem. Lett., 2011, 2, 461-465.
40. Gao, B.-L.; Zhang, C.-M.; Yin, Y.-Z.; Tang, L.-Q.; Liu, Z.-P. Design andsynthesis of potent HIV-1 protease inhibitors incorporatinghydroxyprolinamides as novel P2 ligands. Bioorg. Med. Chem. Lett., 2011,21, 3730-3733.
41. (a)Smith III, A.B.; Charnley, A.K.; Harada, H.; Beiger, J.J.; Cantin, L.D.;Kenesky, C.S.; Hirschmann, R.; Munshi, S.; Olsen, D.B.; Stahlhut, M.W.;Schleif, W.A.; Kuo, L.C. Design, synthesis, and biological evaluation ofmonopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2'side chains. Bioorg. Med. Chem. Lett., 2006, 16, 859-863 (Pubitemid 43059838)
42. (a)Smith III,A.B.; Charnley, A.K.; Hirschmann, R. Acc. Chem. Res., 2011, 44, 180-193.
43. Ghosh, A.K.; Gemma, S.; Simoni, E.; Baldridge, A.; Walters, D.E.; Ide, K.;Tojo, Y.; Koh, Y.; Amano, M.; Mitsuya, H. Synthesis and biologicalevaluation of novel allophenylnorstatine-based HIV-1 protease inhibitorsincorporating high affinity P2-ligands. Bioorg. Med. Chem. Lett., 2010, 20,1241-1246.
44. (a)Ami, E.i.; Nakahara, K.; Sato, A.; Nguyen, J.-T.; Hidaka, K.; Hamada,Y.; Nakatani, S.; Kimura, T.; Hayashi, Y.; Kiso, Y. Synthesis and antiviralproperty of allophenylnorstatine-based HIV protease inhibitors incorporatingd-cysteine derivatives as P2/P3 moieties. Bioorg. Med. Chem. Lett., 2007, 17,4213-4217 (Pubitemid 47021398)
45. (b)Nakatani, S.; Hidaka, K.; Ami, E.; Nakahara, K.; Sato, A.;Nguyen, J.T.; Hamada, Y.; Hori, Y.; Ohnishi, N.; Nagai, A.; Kimura, T.;Hayashi, Y.; Kiso, Y. Combination of non-natural D-amino acid derivativesand allophenylnorstatine-dimethylthioproline scaffold in HIV proteaseinhibitors have high efficacy in mutant HIV. J. Med. Chem., 2008, 51, 2992-3004. (Pubitemid 351706027)
46. Hidaka, K.; Kimura, T.; Abdel-Rahman, H.M.; Nguyen, J.T.; McDaniel,K.F.; Kohlbrenner, W.E.; Molla, A.; Adachi, M.; Tamada, T.; Kuroki, R.;Katsuki, N.; Tanaka, Y.; Matsumoto, H.; Wang, J.; Hayashi, Y.; Kempf,D.J.; Kiso, Y. Small-sized human immunodeficiency virus type-1 proteaseinhibitors containing allophenylnorstatine to explore the S-2' pocket. J. Med.Chem., 2009, 52, 7604-7617.
47. He, M.; Zhang, H.; Yao, X.; Eckart, M.; Zuo, E.; Yang, M. Design, biologicevaluation, and SAR of novel pseudo-peptide incorporating benzheterocyclesas HIV-1 protease inhibitors. Chem. Biol. Drug. Des., 2010, 76, 174-180.
48. Lu, Z.; Raghavan, S.; Bohn, J.; Charest, M.; Stahlhut, M.W.; Rutkowski,C.A.; Somcoe, A.L.; Olsen, D.B.; Schleif, W.A.; Carella, A.; Gabryelski, L.;Jin, L.; Lin, J.H.; Emini, E.; Chapman, K.; Tata, J.R. Design and synthesis ofhighly potent HIV protease inhibitors with activity against resistant virus.Bioorg. Med. Chem. Lett., 2003, 13, 1821-1824. (Pubitemid 36561173)
49. Raghavan, S.; Lu, Z.; Beeson, T.; Chapman, K.T.; Schleif, W.A.; Olsen,D.B.; Stahlhut, M.; Rutkowski, C.A.; Gabryelski, L.; Emini, E.; Tata, J.R.Synthesis of novel HIV protease inhibitors (PI) with activity against PIresistantvirus. Bioorg. Med. Chem. Lett., 2007, 17, 5432-5436. (Pubitemid 47391269)
50. Altman, M.D.; Ali, O.A.; Reddy, G.S.K.K.; Nalam, M.N.L.; Anjum, S.G.;Cao, H.; Chellappan, S.; Kairys, V.; Fernandes, M.X.; Gilson, M.K.;Schiffer, C.A.; Rana, T.M.; Tidor, B. HIV-1 protease inhibitors from inversedesign in the substrate envelope exhibit subnanomolar binding to drugresistantvariants. J. Am. Chem. Soc., 2008, 130, 6099-6113.
51. Nalam, M.N.L.; Ali, A.; Altman, M.D.; Reddy, G.S.K.K.; Chellappan, S.;Kairys, V.; Özen, A.; Cao, H.; Gilson, M.K.; Tidor, B.; Rana, T.M.; Schiffer,C.A. Evaluating the substrate-envelope hypothesis: structural analysis ofnovel HIV-1 protease inhibitors designed to be robust against drugresistance. . J. Virol., 2010, 84, 5368-5378.
52. Sevigny, G.; Stranix, B.; Tian, B.; Dubois, A.; Sauve, G.; Petropoulos, C.;Lie, Y.; Hellmann, N.; Conway, B.; Yelle, J. Antiviral activity and crossresistanceprofile of P-1946, a novel human immunodeficiency virus type 1protease inhibitor. Antiviral Res., 2006, 70, 17-20.
53. Stranix, B.R.; Lavallee, J.F.; Sevigny, G.; Yelle, J.; Perron, V.; LeBerre, N.;Herbart, D.; Wu, J.J. Lysine sulfonamides as novel HIV-protease inhibitors:Nα-epsilon-acyl aromatic ε -amino acids. Bioorg. Med. Chem. Lett., 2006, 16,3459-3462. (Pubitemid 43777110)
54. Dandache, S.; Sevigny, G.; Yelle, J.; Stranix, B.R.; Parkin, N.; Schapiro,J.M.; Wainberg, M.A.; Wu, J.J. In vitro antiviral activity and cross-resistanceprofile of PL-100, a novel protease inhibitor of human immunodeficiencyvirus type 1. Antimicrob. Agents Chemother., 2007, 51, 4036-4043. (Pubitemid 350057803)
55. Jones, K.L.G.; Holloway, M.K.; Su, H.P.; Carroll, S.S.; Burlein, C.; Touch,S.; DiStefano, D.J.; Sanchez, R.I.; Williams, T.M.; Vacca, J.P.; Coburn, C.A.Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors. Bioorg.Med. Chem. Lett., 2010, 20, 4065-4068.
56. Rajapakse, H.A.; Walji, A.M.; Moore, K.P.; Zhu, H.; Mitra, A.W.; Gregro,A.R.; Tinney, E.; Burlein, C.; Touch, S.; Paton, B.L.; Carroll, S.S.;DiStefano, D.J.; Lai, M.-T.; Grobler,J.A.; Sanchez, R.I.; Williams, T.M.;Vacca, J.P.; Nantermet, P.G. Strategies towards improving thepharmacokinetic profile of ε-substituted lysinol-derived HIV proteaseinhibitors. ChemMedChem, 2011, 6, 253-257.
57. Lu, D.; Vince, R. Discovery of potent HIV-1 protease inhibitorsincorporating sulfoximine functionality. Bioorg. Med. Chem. Lett., 2007, 17,5614-5619. (Pubitemid 47391314)
58. Raza, A.; Sham, Y.Y.; Vince, R. Design and synthesis of sulfoximine basedinhibitors for HIV-1 protease. Bioorg. Med. Chem. Lett., 2008, 18, 5406-5410.
59. Lu, D.; Sham, Y.Y.; Vince, R. Design, asymmetric synthesis, and evaluationof pseudosymmetric sulfoximine inhibitors against HIV-1 protease. Bioorg.Med. Chem., 2010, 18, 2037-2048.
60. Clemente, J.C.; Robbins, A.; Grana, P.; Paleo, M.R.; Correa, J.F.; Villaverde,M.C.; Sardina, F.J.; Govindasamy, L.; Agbandje-McKenna, M.; McKenna,R.; Dunn, B.M.; Sussman, F. Design, synthesis, evaluation, andcrystallographic-based structural studies of HIV-1 protease inhibitors withreduced response to the V82A mutation. J. Med. Chem., 2008, 51, 852-860. (Pubitemid 351304694)
61. Chiummiento, L.; Funicello, M.; Lupattelli, P.; Tramutola, F.; Campaner, P.New indolic non-peptidic HIV protease inhibitors from (S)-glycidol:synthesis and preliminary biological activity. Tetrahedron, 2009, 65, 5984-5989.
62. Giffin, M.J.; Heaslet, H.; Brik, A.; Lin, Y.C.; Cauvi, G.; Wong, C.H.;McRee, D.E.; Elder, J.H.; Stout, C.D.; Torbett, B.E. A copper(I)- catalyzed1,2,3-triazole azide-alkyne click compound is a potent inhibitor of amultidrug-resistant HIV-1 protease variant. J. Med. Chem., 2008, 51, 6263-6270.